Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
155 Tumors Trials near New York, NY
Power is an online platform that helps thousands of Tumors patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerRaludotatug Deruxtecan for Cancer
New York, New York
This pan-tumor trial is designed as a signal-seeking trial to assess efficacy and safety of raludotatug deruxtecan (R-DXd) monotherapy in locally advanced or metastatic solid tumors with various cadherin-6 (CDH6) expression levels, including gynecological cancers (endometrial cancer, cervical cancer, and non-high-grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and clear cell renal cell carcinoma \[ccRCC\]).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiovascular Disease, ILD/pneumonitis, Others
Must Not Be Taking:Corticosteroids, CDH6-targeted Agents
200 Participants Needed
TUB-030 for Cancer
New York, New York
The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are:
To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 as a single drug given to patients with solid cancer Researchers will also compare doses of TUB-030 in two specific cancer types, in patients with head and neck cancer and patients with non-small cell lung cancer, to see if TUB-030 works to treat these two solid cancer types and to determine the best dose.
Participants will:
Receive drug TUB-030 every 3 weeks Visit the clinic once every 3 weeks for checkups and tests Answer patient reported outcome questionnaires about their symptoms
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Others
130 Participants Needed
Vorasidenib + Temozolomide for Brain Tumors
New York, New York
The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. The study will begin as a Phase Ib study to determine the RCD and then will transition to a Phase II study to assess the clinical efficacy of vorasidenib at the RCD in combination with TMZ. During the treatment period participants will have study visits on day 1 and 22 of each cycle, with additional visits occurring during the first cycle of the Phase 1b study. Approximately 30 days after treatment has ended, a safety follow-up visit will occur and then participants will be followed for survival every 3 months. Study visits may include questionnaires, blood tests, ECG, vital signs, and a physical examination.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Leptomeningeal Disease, Hepatitis, Others
Must Be Taking:Temozolomide
42 Participants Needed
PBI-410 for Advanced Cancer
New York, New York
This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Brain Metastases, Lung Disease, Others
Must Not Be Taking:Trop-2 ADCs
500 Participants Needed
Ifinatamab Deruxtecan for Cancer
New York, New York
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Spinal Cord Compression, Others
Must Not Be Taking:Steroids, Anticonvulsants
520 Participants Needed
Selinexor for Solid Tumors
New York, New York
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Solid Organ Transplant, Others
Must Not Be Taking:XPO1 Inhibitors
45 Participants Needed
AMG 193 + IDE397 for Solid Cancers
New York, New York
This trial tests the safety and best dose of two drugs, AMG 193 and IDE397, in adults with advanced cancers missing the MTAP gene, especially lung cancer. The goal is to see if this combination can effectively fight these cancers.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Bowel Obstruction, Others
Must Not Be Taking:CYP3A4/5 Inducers, Inhibitors
53 Participants Needed
DB-1311 for Advanced Cancer
New York, New York
This trial tests a new drug, DB-1311, in patients with advanced solid tumors. It aims to find the safest and most effective dose and then confirm its safety and effectiveness in more patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Heart Failure, Lung Diseases, Infections, Others
Must Not Be Taking:B7-H3 Therapy, Topoisomerase Inhibitors
862 Participants Needed
ART6043 for Metastatic Cancer
New York, New York
This trial tests a new cancer drug, ART6043, alone or with other drugs (Olaparib and Niraparib) in patients with advanced cancers that have genetic defects in DNA repair. The treatment aims to exploit the cancer cells' inability to fix their DNA, making it harder for them to survive. Olaparib is used to treat certain cancers by preventing the cancer cells from fixing their DNA, which makes it harder for them to survive.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, MDS/AML, Brain Metastases, Others
Must Be Taking:PARPi
220 Participants Needed
LB101 for Solid Tumors
New York, New York
This trial is testing a new treatment called LB101 on its own in patients with advanced solid tumors. The goal is to see if LB101 is safe, can be tolerated by patients, and if it helps in controlling or shrinking the tumors. The study will also look at how the body processes the treatment and the immune response to it. New studies are looking into different types of treatments for various cancers. Previous concerns about safety had slowed progress, but recent research suggests that new versions of these treatments may be safer and more effective when used with other therapies.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Diseases, HIV, Hepatitis, Others
Must Not Be Taking:Immunosuppressants, Glucocorticoids, Live Vaccines, Others
25 Participants Needed
ART0380 for Cancer
New York, New York
This trial is testing ART0380, an oral cancer drug, in patients with advanced or hard-to-treat cancers. The drug targets a protein that helps cancer cells repair their DNA, making it harder for the cancer to survive. BO-1051 is a new anti-cancer drug that can effectively target a variety of cancer cell lines and inhibit tumor growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Serious Systemic Disorder, Others
Must Not Be Taking:ATR Inhibitors
36 Participants Needed
TNG462 for Solid Cancers
New York, New York
This trial is testing a new oral drug called TNG462 in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these cancer cells grow. The goal is to see if TNG462 can stop the cancer from growing and spreading.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Infection, Liver Disease, HIV, Others
Must Not Be Taking:Antiretrovirals
225 Participants Needed
Triapine + Targeted Radiation for Neuroendocrine Cancer
New York, New York
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Illness, Heart Failure, Others
Must Not Be Taking:Investigational Agents
94 Participants Needed
SAR445877 for Advanced Cancer
New York, New York
This trial tests a new drug, SAR445877, for adults with advanced cancers that are hard to treat. The study will find the best amount to use and check if the drug is safe and works well, both alone and with other treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Cardiac Disease, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants
542 Participants Needed
RP-3500 + Radiation Therapy for Cancer
New York, New York
The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Hypertension, Active Infections, Hepatic Impairment, Others
Must Not Be Taking:Strong CYP3A Inhibitors
84 Participants Needed
MRT-2359 for Solid Tumors
New York, New York
This trial tests a new drug called MRT-2359 that breaks down a protein in cancer cells. It targets patients with certain types of previously treated cancers. The drug aims to destroy a protein crucial for cancer cell survival, potentially stopping or slowing the cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Malabsorption, CNS Involvement, Cardiac Disease, Others
Must Be Taking:Fulvestrant, Enzalutamide
174 Participants Needed
YL201 for Solid Tumors
New York, New York
This trial is testing a new drug called YL201 in patients with advanced solid tumors that don't respond to current treatments. The study will determine the safest dose and see how effective the drug is in treating these tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Cardiovascular, Others
Must Not Be Taking:Topoisomerase Inhibitors, ADCs
312 Participants Needed
AZD9574 for Advanced Solid Tumors
New York, New York
This trial tests AZD9574, a new drug that stops cancer cells from repairing themselves. It targets patients with advanced or relapsed cancers who need new treatment options. The drug is tested alone and in combination with other cancer-fighting drugs.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Severe Pancytopenia, Uncontrolled Seizures, Severe Brain Injury, Others
Must Be Taking:PARPi, TMZ
695 Participants Needed
NVL-655 for NSCLC
New York, New York
This trial is testing a new drug called NVL-655 to see if it is safe and effective for patients with advanced ALK-positive lung cancer and other solid tumors. The drug works by blocking a protein that helps cancer cells grow. The study focuses on patients who have specific genetic changes and may not respond well to standard treatments. Newer treatments have been shown to improve outcomes in ALK-translocated lung cancer compared to older treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Other Oncogenic Driver, Allergy, Others
Must Not Be Taking:Anticancer Therapy
840 Participants Needed
RMC-6236 for Cancer
New York, New York
This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:CNS Tumors, Brain Metastases, GI Impairment, Others
754 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
ORIC-114 for Solid Tumors
New York, New York
This trial tests ORIC-114, a new oral medicine for advanced cancers. It targets proteins that help cancer grow, including in the brain, and is for patients who need new treatment options.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:EGFR T790M Mutation, ILD, Others
350 Participants Needed
Tiragolumab + Atezolizumab for Solid Tumors
New York, New York
This trial studies how well tiragolumab and atezolizumab work in children and adults with difficult-to-treat tumors missing specific genes. These treatments help the immune system attack cancer and stop it from growing. Atezolizumab is an antibody that has been used with other treatments for various cancers.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Pregnancy, Active Autoimmune, Hepatitis, Others
Must Not Be Taking:Systemic Steroids, Immunosuppressants
86 Participants Needed
TNG908 for Solid Tumors
New York, New York
This trial is testing TNG908, an oral drug, in patients with advanced or metastatic solid tumors that have an MTAP deletion. The drug works by blocking a protein that helps these specific cancer cells grow. The study will see if this treatment can help slow down or stop the cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Infection, Liver Disease, Cardiovascular, Others
Must Not Be Taking:Antiretrovirals
192 Participants Needed
Triple Therapy for Brain Cancer
New York, New York
This study will test the safety and effectiveness of a combination of pembrolizumab, olaparib, and temozolomide to see how well these drugs work when given together in people with a glioma that either did not respond to previous treatment or came back after treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Intracranial Hemorrhage, Immunodeficiency, Autoimmune, Others
Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers
57 Participants Needed
NVL-520 for ROS1-Positive Solid Tumors
New York, New York
This trial tests NVL-520, a new drug, for safety and effectiveness in patients with advanced ROS1-positive cancers. It targets those who haven't responded well to other treatments by blocking a protein that helps cancer cells grow. NVL-520 is being tested for its effectiveness in treating advanced ROS1-positive cancers, a targetable mutation in non-small cell lung cancer (NSCLC) that has seen various treatments like crizotinib and entrectinib.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:12+
Key Eligibility Criteria
Disqualifiers:Other Oncogenic Drivers, Allergy, Major Surgery, Others
359 Participants Needed
AMG 193 + Docetaxel for Advanced Solid Cancers
New York, New York
This trial tests AMG 193 in adults with advanced cancers. The drug aims to specifically attack these cancer cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Brain Metastases, Infection, Heart Failure, Others
Must Not Be Taking:CYP3A4 Inducers, Anticoagulants
649 Participants Needed
ASP1570 + Pembrolizumab for Advanced Cancer
New York, New York
This trial is testing ASP1570, a new drug that helps the immune system fight cancer by reactivating T-cells. It targets adults with advanced solid tumors that have spread and are not responding to standard treatments. ASP1570 works by counteracting the signals that tumors use to turn off T-cells. The study will determine the best dose and test its effectiveness alone or with another drug called pembrolizumab.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, CNS Metastases, Others
Must Not Be Taking:CYP2D6 Inhibitors, Steroids
366 Participants Needed
Repotrectinib + Chemotherapy for Cancer
New York, New York
This trial tests the safety and effectiveness of repotrectinib combined with chemotherapy in children and young adults with severe, spreading cancer. The goal is to find the best dose with few side effects and see if it works well to stop cancer growth.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:1 - 25
Key Eligibility Criteria
Disqualifiers:Bone Marrow Disease, Pregnancy, Infections, Others
Must Not Be Taking:CYP3A4 Inhibitors/inducers
77 Participants Needed
AZD0171 + Durvalumab + Chemotherapy for Pancreatic Cancer
New York, New York
This trial is testing a new drug (AZD0171) and an existing drug (durvalumab) along with standard chemotherapy in patients with advanced pancreatic cancer. The goal is to see if this combination can help the immune system fight the cancer while also killing cancer cells directly.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:CNS Metastasis, Thromboembolic Event, Infection, Others
Must Not Be Taking:Immunosuppressants, Live Vaccines
126 Participants Needed
DAY101 for Brain Tumor
New York, New York
This trial is testing a new pill called DAY101 in young patients with certain brain tumors or advanced cancers. The pill works by blocking proteins that help cancer cells grow. The goal is to see if this treatment can control the disease in patients who have specific genetic changes.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:6 - 25
Key Eligibility Criteria
Disqualifiers:Neurofibromatosis Type 1, Others
141 Participants Needed
Know someone looking for new options?
Spread the word